| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/26/2002 | WO2002074234A2 Method and composition for treatment of skeletal dysplasias |
| 09/26/2002 | WO2002074232A2 Antitumor compositions containing taxane derivatives |
| 09/26/2002 | WO2002074193A2 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
| 09/26/2002 | WO2002074158A2 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 09/26/2002 | WO2002074156A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 09/26/2002 | WO2002074050A2 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 09/26/2002 | WO2002074048A2 P-glycoproteins and uses thereof |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002058638A3 Serpin drugs for treatment of hiv infection and method of use thereof |
| 09/26/2002 | WO2002055659A3 Antisense modulation of integrin beta 4 binding protein expression |
| 09/26/2002 | WO2002055064A3 Mucopolysaccharidosis therapies |
| 09/26/2002 | WO2002055019A3 Methods for ameliorating childhood infections |
| 09/26/2002 | WO2002053581A3 Spliceosome mediated rna trans-splicing |
| 09/26/2002 | WO2002049665A3 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002045492A8 Transgenic mice containing polycystin-related gene disruptions |
| 09/26/2002 | WO2002043566A3 Devices and methods for treating low blood sugar levels |
| 09/26/2002 | WO2002040537A3 Analogues and derivatives of gastrin releasing peptide (grp) |
| 09/26/2002 | WO2002038609A3 Apolipoprotein conjugates |
| 09/26/2002 | WO2002032461A3 Protein c or activated protein c-like molecules |
| 09/26/2002 | WO2002032397A8 Electroprocessing in drug delivery and cell encapsulation |
| 09/26/2002 | WO2002030922A3 Dioxolane analogs for improved inter-cellular delivery |
| 09/26/2002 | WO2002030421A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 09/26/2002 | WO2002029084A3 Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| 09/26/2002 | WO2002026996A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 09/26/2002 | WO2002022685A3 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/26/2002 | WO2002022656A3 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
| 09/26/2002 | WO2002015918A3 Method and compositions for promoting osteogenesis |
| 09/26/2002 | WO2002003922A3 Synthetic peptide for neurological disorders |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001092488A3 Regulation of human plc delta-1 |
| 09/26/2002 | WO2001090159B1 Compositions and methods for delivery of a molecule into a cell |
| 09/26/2002 | WO2001085093A9 Compounds and methods for modulating cerebral amyloid angiopathy |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001061019A3 A dominant selectable marker for gene transformation and disruption in yeasts |
| 09/26/2002 | WO2001047953A3 Antibodies against plasma cells |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001023615A9 Anti-aging nucleic acid and protein targets |
| 09/26/2002 | WO2001023430A9 Human chitinase immunoglobulin fusion proteins |
| 09/26/2002 | WO2001023421A9 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 09/26/2002 | WO2001022985A9 Use of pentagastrin to inhibit gastric acid secretion or as a diuretic |
| 09/26/2002 | WO2001019393A9 Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems |
| 09/26/2002 | WO2001019385A9 The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
| 09/26/2002 | WO2001018550A9 Determination of adrenomedullin-binding proteins |
| 09/26/2002 | WO2001016295A9 Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons |
| 09/26/2002 | WO2000074634A9 Methods and compositions for modulating cell proliferation and cell death |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | WO1997019953A8 New lh-rh antagonists with improved effectiveness |
| 09/26/2002 | US20020138880 Isolating a cation transport gene (magnesium transport gene) comprises selecting from suitable vectors expressing plant or animal cDNAs in yeast for clones that confer a high tolerance to aluminum |
| 09/26/2002 | US20020138874 Elongase genes and uses thereof |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138858 Cd39/ecto-adpase as a treatment for thrombotic and ischemic disorders |
| 09/26/2002 | US20020138038 Device and method for dispensing at least two mutually reactive components |
| 09/26/2002 | US20020137942 HIV protease inhibitors; administering to treat AIDS (acquired immune deficiency syndrome) |
| 09/26/2002 | US20020137911 Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| 09/26/2002 | US20020137910 MN gene and protein |
| 09/26/2002 | US20020137906 Nematode Caenorhabditis elegans (C. elegans); lin-8, lin-56, and lin-61 genes and polypeptides involved in cell proliferation; use in diagnosing and treating abnormal cell proliferation |
| 09/26/2002 | US20020137904 Reagents and methods useful for detecting diseases of the gastrointestinal tract |
| 09/26/2002 | US20020137901 Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
| 09/26/2002 | US20020137900 Endothelial cell growth factor, methods of isolation and expression |
| 09/26/2002 | US20020137898 Antibodies to natural killer stimulatory factor |
| 09/26/2002 | US20020137896 Of given amino acid sequence, found in edible mushroom Tricholoma matsutake |
| 09/26/2002 | US20020137895 Methods of protein purification and recovery |
| 09/26/2002 | US20020137894 Megakaryocyte stimulating factors |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137889 Stress resistant retroviruses |
| 09/26/2002 | US20020137886 Insertion of cleavage sites in non-critical regions of the toxins which are susceptible to protease activity in non-target tissues and single chain forms activated by proteases in the target; botulism and tetanus toxins; confine activity to target site; side effect reduction |
| 09/26/2002 | US20020137885 Corticotropin release inhibiting factor and methods of using same |
| 09/26/2002 | US20020137884 Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor |
| 09/26/2002 | US20020137797 Alpha-Difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate |
| 09/26/2002 | US20020137761 Treating tolerance or drug addiction; analgesics |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137738 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/26/2002 | US20020137730 Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| 09/26/2002 | US20020137718 Nucleozymes |
| 09/26/2002 | US20020137715 Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis |
| 09/26/2002 | US20020137712 69109, a novel human tyrosine phosphatase and uses therefor |
| 09/26/2002 | US20020137711 Suppression of hematopoietic enzyme; organ grafting |
| 09/26/2002 | US20020137708 Antitumor agents |
| 09/26/2002 | US20020137703 Genetic engineering; insertion vector into polypeptides |
| 09/26/2002 | US20020137702 Yeast receptor |
| 09/26/2002 | US20020137701 Administering exogenous genes |
| 09/26/2002 | US20020137700 Nucleic acids; genetic engineering |
| 09/26/2002 | US20020137698 Antisense inhibition of rad51 |
| 09/26/2002 | US20020137697 Chimeric receptor genes and cells transformed therewith |
| 09/26/2002 | US20020137696 Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137685 For production of antiinflammatory peptides |
| 09/26/2002 | US20020137684 Polypeptides capable of crossing the small intestine or blood brain barrier; bioavailability |
| 09/26/2002 | US20020137683 For malignant melanoma and carcinoma of colon/rectum, ovaries, lungs, and prostates; epitopic; immunogens which elicit cytotoxic T lymphocyte responses |
| 09/26/2002 | US20020137681 Treatment of demyelinating autoimmune disease with ordered peptides |
| 09/26/2002 | US20020137680 Growth factor expression |
| 09/26/2002 | US20020137679 Thrombospondins-1 and -2 are adhesive glycoproteins proteins that are angiogenesis inhibitors; portions of TSP- 1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin linked to a portion of cartilage oligoeric matrix protein |
| 09/26/2002 | US20020137678 Treatment of ocular neovascularization and related diseases |
| 09/26/2002 | US20020137677 Soluble zalpha11 cytokine receptors |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137675 Polypeptides, termed PROTX polypeptides, as well as polynucleotides encoding PROTX and antibodies that immuno-specifically bind to a PROTX, variant, mutant, or fragment of a PROTX; detection/treatment of pathological states; kits |